Mast cells elicit protection against colorectal tumors by modulating the immune response during early tumorigenic steps

Mast cells (MC) alter the development of colorectal cancer (CRC), although their precise role remains poorly defined. Here we show that MC numbers vary in CRC patients, which directly impacts on lymphocytes population. Mouse-based mechanistic experiments reveal that an intricate MC-lymphocyte axis can either promote or inhibit the CRC development, as well as be pharmacologically explored. Therefore, MC activity can be modulated and inhibit the early steps of CRC development. Overall design: Colon tumor mRNA profiles of AOM-exposed Kit-B6 and Kit-W/sh mice were generated by RNA sequencing using QIAseq Targeted RNAseq Mouse Immuno-Oncology panel and QIAseq Targeted RNA 96-Index I (#333117) in a in MiSeq Sequencing System (Illumina; Illumina MiSeq Reagent Kit v3 - 150 cycles, #15043894). Please note that the records have been updated with additional RNA-seq data from allographic tumor samples on Mar 23, 2023.

肥大细胞（Mast cells, MC）可调控结直肠癌（colorectal cancer, CRC）的发生发展，但其确切功能仍未明确。本研究发现，CRC患者体内MC数量存在个体差异，且该差异直接影响淋巴细胞群体的稳态与组成。基于小鼠模型的机制实验揭示，MC与淋巴细胞间存在复杂的调控轴，该轴既可促进亦可抑制CRC的发生发展，且该调控通路具备药理学干预的可行性。因此，通过调控MC活性可阻断CRC的早期发生进程。实验整体设计：本研究采用QIAseq靶向RNA测序小鼠免疫肿瘤学面板及QIAseq靶向RNA 96-Index I试剂盒（#333117），结合Illumina MiSeq测序系统（Illumina; Illumina MiSeq Reagent Kit v3 - 150个循环，#15043894），对经偶氮甲烷（AOM）处理的Kit-B6及Kit-W/sh小鼠的结肠肿瘤mRNA转录组进行了RNA测序（RNA sequencing）。请注意，本数据集的记录已于2023年3月23日完成更新，新增了异体移植肿瘤样本的RNA-seq数据。